Morphotek Secures Samples from Fox Chase to Develop Companion Tests for Oncology Drugs | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Morphotek said today that it has entered into two agreements with Fox Chase Cancer Center to acquire clinical samples that it will use to develop companion diagnostic assays for use with drugs currently under development at Morphotek.

Morphotek, a subsidiary of Eisai, said it will fund prospective and archival sample collection programs at Fox Chase to obtain samples from patients who are newly diagnosed with cancer or are being treated for a variety of tumor types.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.